Sigma ligands for use in the prevention and/or treatment of post-operative pain

• US 9,844,516 B2
• Filed: 02/04/2011
• Issued: 12/19/2017
• Est. Priority Date: 02/04/2010
• Status: Expired due to Fees

• Current Assignee: Laboratories Del Dr Esteve SA (Corporation Quimico Farmaceutica Esteve SA)
• Original Assignee: Laboratories Del Dr Esteve SA (Corporation Quimico Farmaceutica Esteve SA)
• Inventors: Vela Hernndez, Jos Miguel, Zamanillo-Castanedo, Daniel, Puig Riera de Conias, Margarita
• Primary Examiner(s): Ricci, Craig
• Assistant Examiner(s): Stone, Christopher R
• Application Number:
  US13/574,940
• Publication Number:
  US 20120302568A1
• Time in Patent Office: 2,510 Days
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/416 condensed with carbocyclic ring systems, e.g. indazole
• CPC Class Codes: A61K 31/4196 1,2,4-Triazoles
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

Claims

1. A method of treatment of postoperative pain developed as a consequence of surgery of a patient, which comprises administering to the patient an amount of a sigma ligand effective alone to treat postoperative pain developed as, a consequence of surgery of the patient, wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof.

2. The method according to claim 1, wherein the pain is acute or chronic postoperative pain developed as a consequence of surgery.

3. The method according to claim 1, wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine hydrochloride.

4. The method according to claim 2, wherein the postoperative pain developed as a consequence of surgery is allodynia developed as a consequence of surgery, or hyperalgesia developed as a consequence of surgery.

5. The method according to claim 1, wherein the amount of the sigma ligand is administered prior to surgery.

6. The method according to claim 5, wherein the amount of the sigma ligand is administered 30 minutes, 1 hour, 2 hours, 5 hours, 10 hours, 15 hours, 24 hours, or more, prior to surgery.

7. The method according to claim 1, wherein the amount of the sigma ligand is administered during surgery.

8. The method according to claim 1, wherein the amount of the sigma ligand is administered after surgery.

9. The method according to claim 1, wherein the amount of the sigma ligand is administered during and after surgery.

10. The method according to claim 8 or 9, wherein the amount of the sigma ligand is administered 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 30 hours, 36 hours, or more, after surgery.